Another mam-miR-214b target SIRT1, whose loss relates to glucose-stimulated insulin secretion and activation improves insulin sensitivity of type 2 diabetes [46,47], has been reported to be protective against high-fat diet-induced metabolic damage and thus may be explored as a therapeutic target for type 2 diabetes treatment [47,48]. The gene discussed is INS; the disease is type 2 diabetes mellitus.